Please login to the form below

Not currently logged in
Email:
Password:

Ludwig Hantson

This page shows the latest Ludwig Hantson news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline with $1.2bn Syntimmune buy

Alexion adds to pipeline with $1.2bn Syntimmune buy

According to Alexion chief executive Ludwig Hantson, SYNT001 is “the first, and currently the only, anti-FcRn therapy in clinical development”and has shown proof-of-concept as a way to ... The acquisition of Syntimmune "represents a critical step in

Latest news

  • Alexion adds to pipeline rebuild with $855m Wilson buy Alexion adds to pipeline rebuild with $855m Wilson buy

    Ludwig Hantson, Alexion’s chief executive, said: “The acquisition of Wilson Therapeutics is a strong strategic fit for Alexion given the overlap with our current clinical and commercial focus on metabolic

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    Nevertheless, Baxalta chief executive Ludwig Hantson - who had dismissed Shire's initial overture saying there was little overlap between the companies and that rare disease therapies "require focus" - has now warmed

  • Baxalta spells out opposition to Shire Baxalta spells out opposition to Shire

    Baxalta chief executive Ludwig Hantson said yesterday that Shire's $30bn takeover bid was a "puzzling" approach that would short-change shareholders. ... Hantson insisted Shire's $45-per-share offer is a "lowball valuation" and comes at a time when

  • Shire makes shock $30bn bid for Baxalta Shire makes shock $30bn bid for Baxalta

    Yesterday Shire's CEO Flemming Ornskov wrote to the recently appointed chief at Baxalta, Ludwig Hantson, saying: “ Your lack of engagement has been surprising. ... The specialist in haematology, immunology and cancer therapies has "a solid foundation

  • Baxalta will add $2.5bn in new product turnover by 2020 Baxalta will add $2.5bn in new product turnover by 2020

    The specialist in haematology, immunology and cancer therapies has "a solid foundation and strong momentum," according to Baxter's chief executive-elect Ludwig Hantson, who is due to take charge when

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics